Skip Navigation


JAC Advance Access originally published online on May 22, 2006
Journal of Antimicrobial Chemotherapy 2006 58(1):220-221; doi:10.1093/jac/dkl203
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/1/220-a    most recent
dkl203v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Anderson, P. L.
Right arrow Articles by Kakuda, T. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, P. L.
Right arrow Articles by Kakuda, T. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Correspondence

Comment on: Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir

Peter L. Anderson1,* and Thomas N. Kakuda2

1 University of Colorado at Denver and Health Sciences Center Box C238, 4200 East Ninth Avenue, Denver, CO 80262, USA 2 Human Pharmacokinetics, Tibotec Inc. 1020 Stony Hill Road, Suite 300, Yardley, PA 19067, USA

*Corresponding author. Tel: +1-303-315-1720; Fax: +1-303-315-1721; E-mail: peter.anderson@uchsc.edu

Keywords: pharmacokinetics , pharmacodynamics , drug interactions

The first 10% of the full text of this article appears below.

Sir,

Barreiro and Soriano present an interesting hypothesis for what seems to be a paradoxical depletion of CD4+ cells in the face of virological suppression when the combination of didanosine and tenofovir is used.1 The central tenet of their hypothesis is the inhibition of purine nucleoside phosphorylase (PNP) by tenofovir or its metabolites such that an accumulation of deoxyribonucleotides, particularly dGTP, leads to a specific T-lymphocytopenia. This situation is akin . . . [Full Text of this Article]

Transparency declarations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
P. L. Anderson, T. King, J.-H. Zheng, and S. MaWhinney
Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro
J. Antimicrob. Chemother., October 1, 2008; 62(4): 738 - 745.
[Abstract] [Full Text] [PDF]